Unknown

Dataset Information

0

Therapeutic strategies for sickle cell disease: towards a multi-agent approach.


ABSTRACT: For over 100 years, clinicians and scientists have been unravelling the consequences of the A to T substitution in the ?-globin gene that produces haemoglobin S, which leads to the systemic manifestations of sickle cell disease (SCD), including vaso-occlusion, anaemia, haemolysis, organ injury and pain. However, despite growing understanding of the mechanisms of haemoglobin S polymerization and its effects on red blood cells, only two therapies for SCD - hydroxyurea and L-glutamine - are approved by the US Food and Drug Administration. Moreover, these treatment options do not fully address the manifestations of SCD, which arise from a complex network of interdependent pathophysiological processes. In this article, we review efforts to develop new drugs targeting these processes, including agents that reactivate fetal haemoglobin, anti-sickling agents, anti-adhesion agents, modulators of ischaemia-reperfusion and oxidative stress, agents that counteract free haemoglobin and haem, anti-inflammatory agents, anti-thrombotic agents and anti-platelet agents. We also discuss gene therapy, which holds promise of a cure, although its widespread application is currently limited by technical challenges and the expense of treatment. We thus propose that developing systems-oriented multi-agent strategies on the basis of SCD pathophysiology is needed to improve the quality of life and survival of people with SCD.

SUBMITTER: Telen MJ 

PROVIDER: S-EPMC6645400 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic strategies for sickle cell disease: towards a multi-agent approach.

Telen Marilyn J MJ   Malik Punam P   Vercellotti Gregory M GM  

Nature reviews. Drug discovery 20190201 2


For over 100 years, clinicians and scientists have been unravelling the consequences of the A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the systemic manifestations of sickle cell disease (SCD), including vaso-occlusion, anaemia, haemolysis, organ injury and pain. However, despite growing understanding of the mechanisms of haemoglobin S polymerization and its effects on red blood cells, only two therapies for SCD - hydroxyurea and L-glutamine - are approve  ...[more]

Similar Datasets

| S-EPMC4992628 | biostudies-other
| S-EPMC3031491 | biostudies-literature
| S-EPMC8282668 | biostudies-literature
| S-EPMC4605066 | biostudies-other
| S-EPMC8199244 | biostudies-literature
| S-EPMC6328043 | biostudies-literature
| S-EPMC8459571 | biostudies-literature
| S-EPMC4195245 | biostudies-literature
| S-EPMC6833033 | biostudies-literature
| S-EPMC5012429 | biostudies-literature